Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.49 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114819 | 0.76 | PIK3CA (0.49) | PIK3CAMTOR | |
| SCHEMBL29636514 | 0.75 | KMT2A (0.55) | PIK3CAPIK3CDPIK3CBPIK3CGMEN1 | |
| SCHEMBL14127702 | 0.75 | KMT2A (0.55) | PIK3CAPIK3CDPIK3CBPIK3CGMEN1 | |
| SCHEMBL655444 | 0.72 | EGFR (0.51) | PIK3CAPIK3CDPIK3CBPIK3CGULK1 | |
| SCHEMBL114916 | 0.72 | PIK3CA (0.46) | PIK3CAPIK3CDPIK3CBPIK3CGULK1 | |
| SCHEMBL116773 | 0.71 | PIK3CG (0.55) | PIK3CAPIK3CDPIK3CBPIK3CGULK1 | |
| SCHEMBL117184 | 0.71 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL12276570 | 0.71 | EGFR (0.53) | PIK3CAPIK3CDPIK3CBPIK3CGULK1 | |
| SCHEMBL855547 | 0.70 | MAPT (0.48) | PIK3CAPIK3CDPIK3CBPIK3CGULK1 | |
| SCHEMBL6345655 | 0.69 | PIK3CA (0.50) | PIK3CAPIK3CDPIK3CBPIK3CGULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102548984-A | Inhibitors of PI3 kinase and / or MTOR | AMGEN INC | 2012-07-04 | — | — | CN | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3CD 3/4885PIK3CB 13/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3CD 3/4885PIK3CB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.